Amgen Inc. (AMGN)
Amgen tumbles to year's low despite weightloss trial success
Amgen Inc (NASDAQ:AMGN, ETR:AMG) shares tumbled 11.6% to a year's low after results of a trial for its potential weight-loss drug showed it helped overweight or obese people lose up 20% of weight over a year. The Phase II study showed MariTide enabled up to around 20% average loss of weight without a plateau, with the company saying it is the first obesity treatment at this clinical stage with monthly or less frequent dosing to demonstrate such effective weight-loss capabilities safely.
Cramer's Stop Trading: Amgen
CNBC's Jim Cramer explains why he is keeping an eye on shares of Amgen.
Amgen Reveals Data From Closely Watched Monthly Obesity Drug, With Weight Loss Of Up To 20% At One Year And No Plateau
On Tuesday, Amgen Inc AMGN stock fell during the premarket session after the company released long-anticipated data from the Phase 2 study of MariTide (maridebart cafraglutide, formerly AMG 133) in obese patients.
Amgen Stock Dives Despite Positive Weight-Loss Drug Data. What to Know.
The pharmaceutical company's MariTide treatment performed well in a phase 2 study.
Amgen's stock slides 7.8% after weight-loss drug data lags analyst expectations
Amgen's MariTide achieves up to 20% weight loss in mid-stage trial, but analysts were expecting up to 25%.
Amgen says obesity drug caused up to 20% weight loss after a year, with no plateau
CNBC's Angelica Peebles joins 'Squawk Box' with the latest news.
Amgen says obesity drug caused up to 20% weight loss after a year, with no plateau
Amgen said its experimental weight loss injection helped patients lose up to 20% of their weight on average after a year, with no plateau, in a critical mid-stage trial. But the results appear to be at the low end of Wall Street's expectations.
Amgen drug leads to up to 20% weight loss in trial
Amgen's experimental drug MariTide led to average weight loss of up to 20% in a year-long mid-stage trial of nearly 600 people who were overweight or obese, the company said on Tuesday.
Why Amgen (AMGN) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Investing in Pharma Stocks? Check These 3 Things First
Investing in Pharma Stocks? Check These 3 Things First
Wall Street awaits Amgen weight-loss drug data expected to move shares
Upcoming data from a mid-stage study of Amgen's experimental weight-loss drug MariTide will shed light on how well it might measure up against the popular GLP-1 drugs sold by Eli Lilly and Novo Nordisk.
Amgen Sells Off: Keep Calm And Buy The Dip
Amgen's stock dropped nearly 15% last week due to safety concerns about its GLP-1 candidate MariTide. Amgen's management and analysts downplayed the bone mineral density concerns, emphasizing MariTide's potential and its ongoing Phase II study, which will be reported soon. Amgen's Q3 earnings call highlighted MariTide's promise, with plans for a broad Phase III program targeting obesity and type 2 diabetes.
